translation agency

HIV viremia influences survival in HIV-infected patients.
Yerly S; Perneger T; Hirschel B; Matter L; Malinverni R; Perrin L;
January 30, 1997
Int Conf AIDS. 1996 Jul 7-12;11(2):27 (abstract no. We.B.413). Unique

Objective: To assess if HIV viremia influences survival and clinical progression. Methods: 398 patients who had frozen plasma collected between 1991-93 were selected after stratification by baseline CD4 cell counts (0-49, 50-199, 200-499, and greater than or equal to 500 /mm3). Outcome variables were death and onset of opportunistic infections. Baseline predictors were HIV viremia Roche Amplicor), CD4 cell counts, and clinical stages. Data were analyzed using the Kaplan-Meier method and proportional hazards models. Results: The sample included 309 men and 89 women, aged 18 to 66 years (mean 35, SD 8). During a mean follow-up of 27 months, 160 patients died: survival was 85% after 1 year and 69% after 2 years. At baseline, the log HIV RNA ranged from 2.00 to 6.24 (mean 4.34, SD 0.80) and CD4 cell counts from 2 to 1606/mm3 mean 299, SD 302); 158 patients were in stage A, 116 in stage B and 124 in stage C. These 3 parameters were independently associated with the risk of death (Table). Data on incidence of opportunistic infections will be presented. (table: see text) Conclusion: HIV viremia is a predictor of death independently of CD4 cell counts and clinical stages.